본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Real-World Efficacy and Tolerability of Switching from Oxcarbazepine to Eslicarbazepine Therapy in Children Aged 6 Years or Older with Focal Epilepsy

이용수  0

영문명
발행기관
대한소아신경학회
저자명
Sooyoung Lyu Juhyun Kong Sang Ook Nam Taek Jin Lim Young Mi Kim Gyu Min Yeon Yun-Jin Lee
간행물 정보
『Annals of Child Neurology(구 대한소아신경학회지)』vol.33 no.3, 93~101쪽, 전체 9쪽
주제분류
의약학 > 소아과학
파일형태
PDF
발행일자
2025.07.31
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

Purpose: This study investigated the influence of prior use of oxcarbazepine (OXC) and other anti-seizure medications (ASMs) on seizure outcomes and tolerability when switching from OXC to eslicarbazepine acetate (ESL) or when adding adjunctive ESL therapy. Additionally, we aimed to evaluate other prognostic factors associated with ESL therapy in pediatric focal epilepsy. Methods: ESL adjunctive or switching therapy was initiated in children aged ≥6 years with focal epilepsy. Patients were classified into those who received baseline ASMs including OXC (OXC-P group, switching from OXC) and those who received other ASMs excluding OXC (OXC-N group, adjunctive therapy). Reduction in seizure frequency and adverse events (AEs) were evaluated during follow-up. Results: Seventy-two patients (mean age, 10.9±5.2 years) were included. The mean duration of ESL therapy was 6.1±3.7 months, and the mean maintenance dose was 16.3±5.6 mg/kg/day. The proportion of responders (≥50% reduction in seizure frequency) was 40.3% (29/72), without a significant difference between the OXC-P and OXC-N groups (17/50 [34.0%] vs. 12/22 [54.5%], P=0.169). Moreover, no significant between-group differences were noted in overall AEs (30.0% vs. 27.3%, P=0.981) or the retention rate (82.0% vs. 77.3%, P=0.886). Significant factors associated with a favorable response to ESL treatment were a higher ESL dose, shorter epilepsy duration, and fewer concomitant ASMs. Conclusion: Switching from OXC to ESL or using adjunctive ESL therapy was effective and well-tolerated in children aged ≥6 years with focal epilepsy, irrespective of prior use of OXC in the baseline ASM regimen before initiating ESL therapy.

영문 초록

목차

Introduction
Materials and Methods
Results
Discussion
References

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Sooyoung Lyu,Juhyun Kong,Sang Ook Nam,Taek Jin Lim,Young Mi Kim,Gyu Min Yeon,Yun-Jin Lee. (2025).Real-World Efficacy and Tolerability of Switching from Oxcarbazepine to Eslicarbazepine Therapy in Children Aged 6 Years or Older with Focal Epilepsy. Annals of Child Neurology(구 대한소아신경학회지), 33 (3), 93-101

MLA

Sooyoung Lyu,Juhyun Kong,Sang Ook Nam,Taek Jin Lim,Young Mi Kim,Gyu Min Yeon,Yun-Jin Lee. "Real-World Efficacy and Tolerability of Switching from Oxcarbazepine to Eslicarbazepine Therapy in Children Aged 6 Years or Older with Focal Epilepsy." Annals of Child Neurology(구 대한소아신경학회지), 33.3(2025): 93-101

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제